Evidence map›Paper›PMID 40413207›Full record

ArticleNature communications2025

Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.

Victoria Roulstone, Joan Kyula-Currie, James Wright, Emmanuel C Patin, Isaac Dean, Lu Yu, Aida Barreiro-Alonso, Miriam Melake, Jyoti Choudhary, Richard Elliott and 21 more

Erratum issuedAbstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors.

Victoria Roulstone *The Institute of Cancer Research, London, UK. Victoria.Roulstone@icr.ac.uk.ORCID http://orcid.org/0000-0003-4141-8123
Joan Kyula-Currie *The Institute of Cancer Research, London, UK.
James WrightThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0001-6950-4328
Emmanuel C PatinThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0001-5390-5733
Isaac DeanThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-4750-5335
Lu YuThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0001-8378-9112
Aida Barreiro-AlonsoThe Institute of Cancer Research, London, UK.
Miriam MelakeThe Institute of Cancer Research, London, UK.
Jyoti ChoudharyThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0003-0881-5477
Richard ElliottThe CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0009-0002-0174-5488
Christopher J LordThe CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-3226-0515
David MansfieldThe Institute of Cancer Research, London, UK.
Nik MatthewsThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-0602-1131
Ritika ChauhanThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-1224-9343
Victoria JenningsThe Institute of Cancer Research, London, UK.
Charleen Chan Wah HakThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-6386-5699
Holly BaldockThe Institute of Cancer Research, London, UK.
Francesca ButeraThe Institute of Cancer Research, London, UK.
Elizabeth AppletonThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-8794-3428
Pablo NenclaresThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-1750-3179
Malin PedersenThe Institute of Cancer Research, London, UK.
Shane FooThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0001-6295-7404
Amarin WongariyapakThe Institute of Cancer Research, London, UK.
Antonio RullanThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-7365-9629
Tencho TenevThe Institute of Cancer Research, London, UK.
Pascal MeierThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0003-2760-6523
Richard VileMayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-2192-9372
Hardev PandhaUniversity of Surrey, Guildford, UK.
Alan MelcherThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-2042-3380
Martin McLaughlinThe Institute of Cancer Research, London, UK.
Kevin J HarringtonThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-6014-348X

Funding

Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors.R01CA269384 · NCI · MAYO CLINIC ROCHESTER · PI Richard G. Vile · 2023 to 2026
$1.4M
Cancer Research UK (CRUK) CRM183XNCI NIH HHS R01 CA269384
6 · The paper itself

Abstract

Cytoplasmic pattern recognition receptors (PRR) for double-stranded RNA, such as RIG-I/MDA5, are key mediators of anti-viral responses. Here we screen for synergistic drug-virotherapy combinations and find that the reovirus type III Dearing strain (Rt3D)-palbociclib combination augments oncolytic virus-induced stress responses and increases interferon production and signaling. Data from RIG-I agonist and ER stress-inducing agents further confirms the crosstalk between RNA-sensing and ER stress in inducing cancer cell death and interferon production. Combined Rt3D-palbociclib also increases innate immune activation and IFN-induced HLA expression within tumor cells, with accompanying alterations in the epigenetic landscape and endogenous retroviral (ERV) elements. Analysis of the immunopeptidome in treated cells further reveals changes to HLA-captured peptides, including altered expression of peptides from cancer or testis antigens and ERVs. Our findings thus highlight the crosstalk between stress signaling and PRR activation for mediating enhanced anti-cancer efficacy.

Indexed as

Antineoplastic AgentsEndoplasmic Reticulum StressImmune EvasionNeoplasmsPiperazinesPyridinesRNA, Double-StrandedCell Line, TumorDEAD Box Protein 58HumansImmunity, InnateInterferonsOncolytic VirusesReceptors, ImmunologicReceptors, Pattern RecognitionSignal TransductionAntineoplastic AgentsDEAD Box Protein 58InterferonsPiperazinesPyridinesReceptors, ImmunologicReceptors, Pattern RecognitionRIGI protein, humanRNA, Double-Stranded

Identifiers

PMID40413207
PMCPMC12103499

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.